INS and metabolic syndrome: The exact mechanism for dyslipidemias is not precisely understood, but may be related to the inhibition of insulin-mediated lipid metabolism, decreased lipoprotein lipase activity, and/or an increase in circulating lipoproteins (38–41).While the vast majority of blood lipid elevations are mild to moderate, there are rare reports in human literature describing severe triglyceride elevations developing secondary to rapamycin therapy (42–44).